IMRX Immuneering Corp

$IMRX on the cover of Cancer research. Now maybe a bit of the Pancreatic Cancer spotlight shines here

$IMRX this is basically trading at cash value now. The med is valued at almost nothing .. Either us bulls are stupid, or people are going to make a lot of money buying down here in a year or 2

$IMRX Bought another 1,000 I think I’m at about 14,000 shares. As my Italian friend used to say “What are you gonna do?!?” Spoken with thick accent of course. Cap

$IMRX Today's earnings report caught me by surprise, as I was expecting the report on Nov 11. Let's see if the market reacts to the headline ($IMRX misses with loss larger than expected) or to the details (increased expenses because the Phase 3 study is increasing the # of participants and the timeline). Good news in the details, but how will the market react?

$IMRX Q3 '26 Earnings Results & Recap Immuneering expects existing cash, cash equivalents and marketable securities as of September 30, 2026 to fund development and operations into fourth quarter of 2028, shortened from 2029.

$IMRX They have really increased international sites- Australia Georgia (Tblisi) Germany Hungary Spain Romania Poland UK The extra expenses brings future benefits such as accelerated global approval and population diversity. If the trial goes well, this can be well worth it. ( I would have liked to see an Asian site but none so far - Japan has a high panc ca rate )

$IMRX other than the fact that this had no business being at $3.50 … anyone have any idea what the renewed interest is about ? Finally got ridiculously cheap I guess. Cap

$IMRX listening to the interview of Ben Zeskind posted by below and making special note of how Zeskind displays a wide smile when discussing Andrew Gengos, the CFO gives me renewed hope in this stock. It may take until mid-2028 to realize the full vlaue of $IMRX but that full value is worth the wait. Who knows what surprises might crop up in the interim. I highly recommend that people watch the full interview.

$IMRX Picked some up here. Made good money here in the past from similar levels and if anything, things seem even better now.

$IMRX upper $3’s and low $4’s has been a great place to buy this year. Hopefully we will see a bounce as we get closer to the October presentation

$IMRX ouch! Someone is going to make a lot of money if they buy here and hold until phase 3 gets near ending

$IMRX dislocation before potential run. Technicals are playing into that as well. If their data even hints at positive endpoints, it’ll run.

$IMRX I'm going to close my eyes now, and hope that when I awake, this jump will still be there. I've seen this game before. Keeping my fingers crossed.

$IMRX slow end to recruiting...when it changes to "Active, not recruiting" the stock will get a boost. RVMD was from 17-60 for 5 years before Merck offered a buyout in Jan 2026. Skyrocketed then collapsed a little before FDA approval skyrocketed it to all time highs. IMRX needs confirmation from an ** RCT study ** (not necessarily FDA approval but interim data , hopefully mid 2027) or a buyout offer for it to skyrocket too. It still has all the makings of wealth generating stock in the future.

$IMRX At this price the company should start buying back shares to sell later above $9. They absolutely have to counter this short attack.

$IMRX 15-25 days to cover short interest at current volumes. any news and this could pop.. cant believe we are trading sub 4.

$IMRX A full year of nothingness. Great news doesn't matter anymore. It is so controlled IMO. How can this only move sideways or down? I see stocks with 1 million caps jump every day and hold at $4. This company wants to cure PC, but it will give you a heart attack on the way. So infuriating.

$IMRX 🏥 Immuneering Corporation reports Phase 3 MAPKeeper 301 enrollment ahead of schedule, expanding the target from 510 to 570 patients and potentially accelerating mid-2028 topline data, while extending Phase 2 pancreatic cancer follow-up with updated data expected in H1 2027. Prioritized by relevance

$IMRX This is not market related. This is deliberate. How many days will this sock frop 2 or 3% before the management does ANYTHING to stop it?

$IMRX Good luck to $RVMD $VSTM and other RAS inhibitors - especially with some recent concerns on $RVMD’s efficacy - but hopefully these inhibitors help PDAC patients. This is all occurring at the top of the MAPK pathway. The great news is - $IMRX’s Atebi is an MEK inhibitor working downstream on the MAPK pathway. Should $IMRX’s current Phase 3 trial (n=510) - replicate its amazing Phase 2 data on 55 patients (mOS 17.3mos - excellent tolerability) - then patients will potentially have a multitude of options. However the RAS protocol plays out - downstream Atebi would be a viable option - either - on its own (combo with chemo) - or together with the upstream RAS inhibitor. The risk/reward of $IMRX is incredible Market Caps $IMRX 250M $RVMD 41B I am not a scientist or a doctor - would love for someone to support or counter above thought process